AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10412270 — intervention group
Group type: EXPERIMENTAL
Intervention: Bax expression in aneuploid cases
Number of subjects: 114
Study 7587851 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple insulin injection therapy (MIT)
Number of subjects: 76
Study 7587851 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy (CIT)
Number of subjects: 76
Study 2262314 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 62
Study 2262314 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 62
Study 424591 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruletide (0.3 microgram/kg)
Number of subjects: 81
Study 31887277 — intervention group
Group type: EXPERIMENTAL
Intervention: T2 magnetic resonance (T2MR)
Number of subjects: 100
Study 30720541 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ripasudil 0.4% (Glanatec) 4 times a day for 2 months
Number of subjects: 18
Study 30720541 — intervention group
Group type: COMPARATOR
Intervention: No ripasudil (control group)
Number of subjects: 18
Study 30720541 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ripasudil 0.4% (Glanatec)
Number of subjects: 18
Study 27528215 — intervention group
Group type: EXPERIMENTAL
Intervention: Education based on phosphorus‐reducing techniques in food preparation and two hospital meals prepared using suggested cooking methods
Number of subjects: 47
Study 27528215 — intervention group
Group type: COMPARATOR
Intervention: Standard education program
Number of subjects: 47
Study 26442397 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine group (group N) received bupivacaine 20 mg combined with 25 µg neostigmine.
Number of subjects: 60
Study 26442397 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C) received bupivacaine 20 mg combined with 0.5ml distilled water.
Number of subjects: 60
Study 23833985 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery with skin grafting (Group B)
Number of subjects: 120
Study 23833985 — intervention group
Group type: COMPARATOR
Intervention: Surgery without skin grafting (Group A)
Number of subjects: 120
Study 23833985 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery with skin grafting (Group A)
Number of subjects: 120
Study 21829046 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET)
Number of subjects: 28
Study 21829046 — intervention group
Group type: COMPARATOR
Intervention: Stress Inoculation Training (SIT)
Number of subjects: 28
Study 19268411 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversion from catheter to permanent vascular access (AVF/AVG)
Number of subjects: 4532
Study 19268411 — intervention group
Group type: COMPARATOR
Intervention: Conversion from permanent vascular access (AVF/AVG) to catheter
Number of subjects: 4532
Study 16876171 — intervention group
Group type: EXPERIMENTAL
Intervention: B vitamins and antioxidants (verum)
Number of subjects: 123
Study 16876171 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 123
Study 14681344 — intervention group
Group type: EXPERIMENTAL
Intervention: YH1885 60 mg single dose
Number of subjects: 46
Study 14681344 — intervention group
Group type: EXPERIMENTAL
Intervention: YH1885 100 mg single dose
Number of subjects: 46
Study 14681344 — intervention group
Group type: EXPERIMENTAL
Intervention: YH1885 150 mg single dose
Number of subjects: 46
Study 14681344 — intervention group
Group type: EXPERIMENTAL
Intervention: YH1885 200 mg single dose
Number of subjects: 46
Study 14681344 — intervention group
Group type: EXPERIMENTAL
Intervention: YH1885 300 mg single dose
Number of subjects: 46
Study 14681344 — intervention group
Group type: EXPERIMENTAL
Intervention: YH1885 150 mg multiple doses (once-daily for 7 days)
Number of subjects: 46
Study 14681344 — intervention group
Group type: EXPERIMENTAL
Intervention: YH1885 300 mg multiple doses (once-daily for 7 days)
Number of subjects: 46
Study 14681344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 11792041 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-fast low-angle rapid acquisition and relaxation enhancement (UFLARE)
Number of subjects: 100
Study 11792041 — intervention group
Group type: COMPARATOR
Intervention: Routine T2-weighted spin echo images
Number of subjects: 100
Study 9488264 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery in patients with PSX
Number of subjects: 50
Study 9488264 — intervention group
Group type: COMPARATOR
Intervention: Cataract surgery in control patients
Number of subjects: 50
Study 7988781 — intervention group
Group type: COMPARATOR
Intervention: Microalbuminuria group (n = 14)
Number of subjects: 37
Study 7988781 — intervention group
Group type: COMPARATOR
Intervention: Macroalbuminuria group (n = 11)
Number of subjects: 37
Study 7988781 — intervention group
Group type: COMPARATOR
Intervention: Microalbuminuria and Macroalbuminuria groups
Number of subjects: 37
Study 2471438 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron
Number of subjects: 213
Study 2471438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study 47702 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 0
Study 47702 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinoid Ro 1-8307
Number of subjects: 0
Study 30480487 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous Blood Patch Injection (ABPI)
Number of subjects: 453
Study 30480487 — intervention group
Group type: COMPARATOR
Intervention: Hydrogel Plug
Number of subjects: 453
Study 28500875 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular setback (group A; n = 11)
Number of subjects: 35
Study 28500875 — intervention group
Group type: EXPERIMENTAL
Intervention: Advancement genioplasty (group B; n = 12)
Number of subjects: 35
Study 28500875 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular setback plus advancement genioplasty (group C; n = 12)
Number of subjects: 35
Study 25864150 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer group intervention (six sessions offered to same-gender groups by trained volunteers)
Number of subjects: 415
Study 25864150 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer group intervention
Number of subjects: 415
Study 25864150 — intervention group
Group type: COMPARATOR
Intervention: Non-participants in the intervention district
Number of subjects: 415
Study 25864150 — intervention group
Group type: EXPERIMENTAL
Intervention: Community HIV prevention
Number of subjects: 415
Study 23721033 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal appliance therapy
Number of subjects: 120
Study 23721033 — intervention group
Group type: COMPARATOR
Intervention: Control (palatal appliance)
Number of subjects: 120
Study 21590762 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 99
Study 21590762 — intervention group
Group type: COMPARATOR
Intervention: Spinal analgesia
Number of subjects: 99
Study 21590762 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 99
Study 19040623 — intervention group
Group type: EXPERIMENTAL
Intervention: Lodenafil carbonate 80 mg
Number of subjects: 72
Study 19040623 — intervention group
Group type: EXPERIMENTAL
Intervention: Lodenafil carbonate 40 mg
Number of subjects: 72
Study 19040623 — intervention group
Group type: EXPERIMENTAL
Intervention: Lodenafil carbonate 20 mg
Number of subjects: 72
Study 19040623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 16546471 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone intake (75 mg of isoflavones conjugates per day)
Number of subjects: 128
Study 16546471 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone combined with walking
Number of subjects: 128
Study 16546471 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with walking (3 times per week)
Number of subjects: 128
Study 16546471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 15618834 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitors
Number of subjects: 10
Study 11418493 — intervention group
Group type: EXPERIMENTAL
Intervention: PROP filter papers
Number of subjects: 742
Study 9302754 — intervention group
Group type: COMPARATOR
Intervention: DTPw vaccine
Number of subjects: 106
Study 9302754 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPw-HB vaccine
Number of subjects: 106
Study 8437326 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-lumen catheters with Vitacuff application and a semiocclusive dressing material
Number of subjects: 50
Study 8437326 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-lumen tunneled catheters with collodion as a dressing material
Number of subjects: 50
Study 8437326 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-lumen tunneled catheters with a semiocclusive dressing
Number of subjects: 50
Study 2876575 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium (P)
Number of subjects: 30
Study 2876575 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium (V)
Number of subjects: 30
Study 2876575 — intervention group
Group type: COMPARATOR
Intervention: Atracurium (A)
Number of subjects: 30
Study 29630706 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative emphasizing violence
Number of subjects: 1326
Study 29630706 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative emphasizing systemic barriers to treatment
Number of subjects: 1326
Study 29630706 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative emphasizing successful treatment and recovery
Number of subjects: 1326
Study 29630706 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 1326
Study 26823137 — intervention group
Group type: EXPERIMENTAL
Intervention: High volume IV fluid (20 mL/kg bolus + 1.5 × maintenance rate)
Number of subjects: 50
Study 26823137 — intervention group
Group type: COMPARATOR
Intervention: Low volume IV fluid (10 mL/kg bolus + 1.25 × maintenance rate)
Number of subjects: 50
Study 24766353 — intervention group
Group type: EXPERIMENTAL
Intervention: Hammock sleep (n = 14)
Number of subjects: 23
Study 24766353 — intervention group
Group type: COMPARATOR
Intervention: Bassinet sleep (n = 9)
Number of subjects: 23
Study 22920928 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of Q waves on baseline electrocardiogram
Number of subjects: 4530
Study 22920928 — intervention group
Group type: COMPARATOR
Intervention: Time from symptom onset to PCI >3 hours
Number of subjects: 4530
Study 20106580 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 mg of tartrazine dye
Number of subjects: 26
Study 20106580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 18179315 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit tests with high structural fit
Number of subjects: 0
Study 18179315 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit tests with high structural fit
Number of subjects: 0
Study 18179315 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit tests with low structural fit
Number of subjects: 0
Study 18179315 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit tests with low structural fit
Number of subjects: 0
Study 18179315 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect misattribution procedure
Number of subjects: 0
Study 15938775 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided immature follicle aspiration (IMFA) with slight amount of human menopausal gonadotropin (hMG)
Number of subjects: 71
Study 15938775 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hMG)
Number of subjects: 71
Study 12600913 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose milrinone (75-microg/kg bolus followed by a 0.75-microg/kg per min infusion for 35 hours)
Number of subjects: 238
Study 12600913 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose milrinone (25-microg/kg bolus followed by a 0.25-microg/kg per min infusion for 35 hours)
Number of subjects: 238
Study 12600913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study 12600913 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose milrinone
Number of subjects: 238
Study 11124928 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% w/w amethocaine gel
Number of subjects: 60
Study 11124928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9513912 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic biopsy scores at months 3 and 6
Number of subjects: 71
Study 9513912 — intervention group
Group type: EXPERIMENTAL
Intervention: Late rejections (months 4 to 6)
Number of subjects: 71
Study 9513912 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) levels (months 1 to 2)
Number of subjects: 71
Study 9513912 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor age
Number of subjects: 71
Study 9513912 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor age and chronic biopsy score > or = 2 at 6 months
Number of subjects: 71
Study 7892022 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 75 mg (slow-release formulation)
Number of subjects: 0
Study 7892022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3150950 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate 100 mg per day for 5 days (CC-5)
Number of subjects: 5
Study 3150950 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate 100 mg per day for 15 days (CC-15)
Number of subjects: 5
Study 31736279 — intervention group
Group type: EXPERIMENTAL
Intervention: Macular buckling
Number of subjects: 80
Study 31736279 — intervention group
Group type: COMPARATOR
Intervention: Vitrectomy
Number of subjects: 80
Study 29912467 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-disciplinary advanced allied health practitioners (AHPs), n = 172
Number of subjects: 256
Study 29912467 — intervention group
Group type: COMPARATOR
Intervention: Standard allied health (AH), n = 84
Number of subjects: 256
Study 28577395 — intervention group
Group type: EXPERIMENTAL
Intervention: More-skilled participants
Number of subjects: 34
Study 28577395 — intervention group
Group type: COMPARATOR
Intervention: Less-skilled participants
Number of subjects: 34
Study 25993904 — intervention group
Group type: COMPARATOR
Intervention: Conventional pressure dressing
Number of subjects: 46
Study 25993904 — intervention group
Group type: EXPERIMENTAL
Intervention: New compression tool
Number of subjects: 46
Study 23888935 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted conditions
Number of subjects: 0
Study 23888935 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat meal
Number of subjects: 0
Study 23888935 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 0
Study 21740390 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS-guided TBNA
Number of subjects: 60
Study 21740390 — intervention group
Group type: COMPARATOR
Intervention: Conventional TBNA
Number of subjects: 60
Study 21740390 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS-guided TBNA in subcarinal lymph nodes
Number of subjects: 60
Study 21740390 — intervention group
Group type: COMPARATOR
Intervention: Conventional TBNA in subcarinal lymph nodes
Number of subjects: 60
Study 21740390 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS-guided TBNA in other mediastinal lymph nodes
Number of subjects: 60
Study 21740390 — intervention group
Group type: COMPARATOR
Intervention: Conventional TBNA in other mediastinal lymph nodes
Number of subjects: 60
Study 19225700 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education (54 subjects)
Number of subjects: 104
Study 19225700 — intervention group
Group type: COMPARATOR
Intervention: Individual education (50 subjects)
Number of subjects: 104
Study 16352692 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/d)
Number of subjects: 99
Study 16352692 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (continuation)
Number of subjects: 99
Study 16352692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 16352692 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of alendronate
Number of subjects: 99
Study 15094260 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine only
Number of subjects: 73
Study 15094260 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine combined with cognitive group-therapy
Number of subjects: 73
Study 15094260 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with personality disorder or social phobia)
Number of subjects: 73
Study 10757131 — intervention group
Group type: EXPERIMENTAL
Intervention: naltrexone
Number of subjects: 25
Study 10757131 — intervention group
Group type: EXPERIMENTAL
Intervention: nalmefene
Number of subjects: 25
Study 10757131 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study 9547164 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) levels of IL-6 in AD patients
Number of subjects: 35
Study 9547164 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) levels of soluble IL-6 receptor (sIL-6R) in AD patients
Number of subjects: 35
Study 9547164 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) levels of soluble gp130 (sgp130) in AD patients
Number of subjects: 35
Study 9547164 — intervention group
Group type: COMPARATOR
Intervention: Cerebrospinal fluid (CSF) levels of sgp130 in all individuals
Number of subjects: 35
Study 8341439 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate cream 0.1% applied daily
Number of subjects: 58
Study 8341439 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone valerate cream 0.1% applied twice daily
Number of subjects: 58
Study 31009427 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Frequency Resistance Training (HFRT)
Number of subjects: 18
Study 31009427 — intervention group
Group type: COMPARATOR
Intervention: Low-Frequency Resistance Training (LFRT)
Number of subjects: 18
Study 31633603 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed therapy (GDT)
Number of subjects: 287
Study 31633603 — intervention group
Group type: COMPARATOR
Intervention: Usual patient care
Number of subjects: 287
Study 29141040 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (oral contraceptive pills Nordette® or Naproxen Naprosyn®)
Number of subjects: 67
Study 29141040 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency endometrial ablation (REA)
Number of subjects: 67
Study 29141040 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct medical costs for REA
Number of subjects: 67
Study 29141040 — intervention group
Group type: EXPERIMENTAL
Intervention: Total costs including indirect costs for REA
Number of subjects: 67
Study 25377934 — intervention group
Group type: EXPERIMENTAL
Intervention: Video modelling intervention
Number of subjects: 80
Study 25377934 — intervention group
Group type: COMPARATOR
Intervention: Control video (oral hygiene instruction)
Number of subjects: 80
Study 23937387 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol ER (25-200 mg bid)
Number of subjects: 343
Study 23937387 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone CR (5-40 mg bid)
Number of subjects: 343
Study 20952051 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid resin composite with an intermediate layer of flowable resin composite
Number of subjects: 46
Study 20952051 — intervention group
Group type: COMPARATOR
Intervention: Hybrid resin composite without an intermediate layer of flowable resin composite
Number of subjects: 46
Study 18435378 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable composites (Gradia LoFlo; Filtek Supreme XT Flow)
Number of subjects: 30
Study 18435378 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesives (Adper Scotchbond 1XT, Scotchbond Multi‐Purpose)
Number of subjects: 30
Study 18435378 — intervention group
Group type: COMPARATOR
Intervention: Control (no intermediate agent applied)
Number of subjects: 30
Study 16598527 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation in high-risk patients with AF
Number of subjects: 128
Study 16598527 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with AF without echocardiographic risk factors)
Number of subjects: 128
Study 12560311 — intervention group
Group type: EXPERIMENTAL
Intervention: Morbid obesity (SG)
Number of subjects: 200
Study 12560311 — intervention group
Group type: COMPARATOR
Intervention: Non-obese (CG)
Number of subjects: 200
Study 10837379 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily
Number of subjects: 224
Study 10837379 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide 2% three times daily
Number of subjects: 224
Study 9397397 — intervention group
Group type: EXPERIMENTAL
Intervention: High-DHA diet (6 g/d of DHA in the form of a triglyceride containing 40% DHA)
Number of subjects: 10
Study 9397397 — intervention group
Group type: COMPARATOR
Intervention: Low-DHA diet (< 50 mg/d of DHA)
Number of subjects: 10
Study 9397397 — intervention group
Group type: EXPERIMENTAL
Intervention: High-DHA diet
Number of subjects: 10
Study 8475977 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 40
Study 8475977 — intervention group
Group type: COMPARATOR
Intervention: Dihydralazine
Number of subjects: 40
Study 3812046 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 60
Study 3812046 — intervention group
Group type: EXPERIMENTAL
Intervention: Focussed smoking
Number of subjects: 60
Study 3812046 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention placebo
Number of subjects: 60
Study 3812046 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 60
Study 29684832 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose (0.2 ml/kg of 20%) plus non-nutritive sucking group
Number of subjects: 86
Study 29684832 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nutritive sucking group
Number of subjects: 86
Study 29684832 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose (0.2 ml/kg of 20%) group
Number of subjects: 86
Study 29684832 — intervention group
Group type: COMPARATOR
Intervention: Routine care group
Number of subjects: 86
Study 27084093 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic school meals rich in fish, vegetables, and potatoes
Number of subjects: 523
Study 27084093 — intervention group
Group type: EXPERIMENTAL
Intervention: Potato intake
Number of subjects: 523
Study 27084093 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain, dietary fiber, protein, and fat intakes
Number of subjects: 523